back to Meetings page
- IMMPACT-XIII Slide Presentations
- 1. Assay sensitivity: general issues and considerations
- Michael Rowbotham, MD
- 2. Increasing the reliability, validity, and responsiveness of pain intensity ratings
- Mark Jensen, PhD
- 3. Implications of new FDA patient-reported outcomes guidance for assessing pain intensity
- Laurie Burke, PhD
- 4. Comments on Rowbotham, Jensen, and Burke presentations
- Ian Gilron, MD
- 5. Improving assay sensitivity in proof-of-concept (i.e., Phase 2) trials: review of existing data and future directions
- Nathaniel Katz, MD
- 6. Improving assay sensitivity in confirmatory (i.e., Phase 3) trials: review of existing data and future directions
- Robert Dworkin, PhD
- 7. Comments on Katz and Dworkin presentations
- Srinivasa Raja, MD
- 8. Regulatory perspective on improving assay sensitivity
- Bob Rappaport, MD